Company Overview - Cidara Therapeutics, Inc. is a biotechnology company focused on developing innovative anti-infective therapies, particularly for high-mortality fungal and viral diseases [6][10] - The company's lead product candidate is rezafungin acetate, a next-generation antifungal, and it also utilizes the Cloudbreak platform for targeted antiviral conjugates [10] Recent Developments - On November 14, 2025, Bain Capital Life Sciences Investors, LLC disclosed the purchase of 520,310 shares of Cidara Therapeutics, increasing its position value by approximately $167.48 million [2][3][7] - Following this transaction, Bain Capital's stake in Cidara rose to 3,020,990 shares, valued at $289.29 million, making it the fund's 3rd-largest holding, accounting for about 19.2% of its assets under management (AUM) [3][4][7] Financial Metrics - As of November 14, 2025, Cidara Therapeutics had a market capitalization of $5.52 billion and a net income of -$184.80 million [5] - The share price on the same date was $217.71, reflecting a significant increase of 1,403.5% over the past year, outperforming the S&P 500 by 1,389.79 percentage points [4][5] Investment Position - Bain Capital Life Sciences Investors held a total of 21 reportable positions at the end of the quarter, with total 13F AUM of $1.51 billion [4] - The top holdings of the fund included NASDAQ: HTFL at $419.00 million (27.8% of AUM), NASDAQ: NAMS at $304.85 million (20.2% of AUM), and NASDAQ: CDTX at $289.29 million (19.2% of AUM) [8]

Core Insights - Cidara Therapeutics is focused on developing innovative anti-infective therapies, particularly through its Cloudbreak® platform for drug-Fc conjugates aimed at serious infections [1] - The company has received an optimistic price target of $153 from JMP Securities, indicating a potential increase of 73.23% from its current trading price [2][6] - Cidara's Phase 3 trial for CD388, a non-vaccine treatment for seasonal influenza, has been accelerated to start in fall 2025 following a positive meeting with the FDA [3][6] Company Developments - The Phase 3 trial for CD388 will now include a broader population, targeting adults over 65, individuals with high-risk co-morbidities, and those with compromised immune systems, which may enhance the drug's market appeal [4][6] - As of the latest update, Cidara's stock is priced at $88.58, reflecting a 20.53% increase, with a market capitalization of $2.25 billion [5]